Market Place
Sourcing Support
Vaxcyte Starts Phase 2 Study of VAX-31 in Infants
03 Dec 2024 //
GLOBENEWSWIRE
Alexandria Real Estate Announces Lease with Vaxcyte at Campus
21 Nov 2024 //
PR NEWSWIRE
Vaxcyte Regulatory Updates on VAX-31 Pediatric & Adult Programs
12 Nov 2024 //
GLOBENEWSWIRE
Vaxcyte Reports Q3 2024 Financial Results & Business Update
05 Nov 2024 //
GLOBENEWSWIRE
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
11 Sep 2024 //
GLOBENEWSWIRE
Vaxcyte Closes $1.5B Public Offering With Full Underwriters` Option
06 Sep 2024 //
GLOBENEWSWIRE
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
04 Sep 2024 //
GLOBENEWSWIRE
Vaxcyte`s `stunning` 31-valent pneumococcal vaccine win against Pfizer`s Prevnar
04 Sep 2024 //
FIERCE BIOTECH
Vaxcyte Announces Public Offering of Common Stock and Pre-Funded Warrants
03 Sep 2024 //
GLOBENEWSWIRE
Vaxcyte To Host Webcast On Phase 1/2 Results Of VAX-31 Pneumococcal Vaccine
02 Sep 2024 //
GLOBENEWSWIRE
Vaxcyte Reports Q2 2024 Results And Provides Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Vaxcyte Appoints John Furey to Board of Directors
02 Jul 2024 //
GLOBENEWSWIRE
Vaxcyte Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
02 Apr 2024 //
GLOBENEWSWIRE
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24
04 Mar 2024 //
GLOBENEWSWIRE
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Vaxcyte Announces Closing of $862.5 Million Public Offering
02 Feb 2024 //
GLOBENEWSWIRE
Vaxcyte to Present at the 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock
30 Jan 2024 //
GLOBENEWSWIRE
Vaxcyte Announces Pricing of $750 Million Public Offering
30 Jan 2024 //
GLOBENEWSWIRE
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31
29 Jan 2024 //
PRESS RELEASE
Vaxcyte Appoints Whitney Jones as Chief People Officer
16 Jan 2024 //
GLOBENEWSWIRE
Vaxcyte Provides Progress Update on Potential Best-in-Class PCV Franchise
04 Jan 2024 //
GLOBENEWSWIRE
Vaxcyte Appoints Jacks Lee to Board of Directors
28 Nov 2023 //
GLOBENEWSWIRE
Vaxcyte Enters into Manufacturing Rights Agreement with Sutro Biopharma
27 Nov 2023 //
GLOBENEWSWIRE
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31
09 Nov 2023 //
GLOBENEWSWIRE
Vaxcyte Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Vaxcyte to Present at Upcoming Investor Conferences
31 Oct 2023 //
GLOBENEWSWIRE
Vaxcyte Announces FDA Clearance of Investigational NDA for VAX-31
19 Oct 2023 //
GLOBENEWSWIRE
Vaxcyte & Lonza Expand Collaboration for Global Commercial Manufacturing of PCVs
16 Oct 2023 //
GLOBENEWSWIRE
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
19 Sep 2023 //
GLOBENEWSWIRE
Vaxcyte Reports Second Quarter 2023 Financial Results & Provides Business Update
08 Aug 2023 //
GLOBENEWSWIRE
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24
11 Jul 2023 //
GLOBENEWSWIRE
Vaxcyte Mourns the Sudden Passing of Board Member Michael Kamarck
06 Jul 2023 //
PRESS RELEASE
Vaxcyte to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Vaxcyte Reports 1Q 2023 FYR and Provides Business Update
08 May 2023 //
GLOBENEWSWIRE
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
03 May 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Closing of $575 M PO Including Full Exercise of Underwriters
21 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Pricing of $500 Million Public Offering
19 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
18 Apr 2023 //
FINANCE YAHOO
Vaxcyte Reports +Ve Data from Ph2 Study of its 24-Valent Pneumococcal VAX-24
17 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock
17 Apr 2023 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
17 Apr 2023 //
PRESS RELEASE
Vaxcyte`s pneumococcal shot holds its own against Prevnar
17 Apr 2023 //
FIERCE BIOTECH
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24
30 Mar 2023 //
GLOBENEWSWIRE
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte Announces FDA Clearance of Investigational NDA for VAX-24
21 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results
16 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Vaxcyte VAX-24 Granted FDA Breakthrough Therapy Designation
05 Jan 2023 //
GLOBENEWSWIRE
Sutro Biopharma & Vaxcyte Enter into Option Grant Agreement for the Development
20 Dec 2022 //
GLOBENEWSWIRE
Vaxcyte Reports 3Q 2022 Financial Results and Provides Business Update
07 Nov 2022 //
GLOBENEWSWIRE
Vaxcyte`s data lead to $600M haul, while Taysha looks to raise cash after Astellas deal
27 Oct 2022 //
ENDPTS
Vaxcyte Announces Pricing of $600 Million Public Offering
26 Oct 2022 //
PRESS RELEASE
Vaxcyte`s 24-valent pneumococcal shot will seek a pivotal win
25 Oct 2022 //
ENPTS
Vaxcyte Reports Data from Ph1/2 Study of 24-Valent Pneumococcal Conjugate
24 Oct 2022 //
GLOBENEWSWIRE
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock
24 Oct 2022 //
GLOBENEWSWIRE
Vaxcyte Expands Executive Leadership Team with Key Appointments
11 Oct 2022 //
GLOBENEWSWIRE
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability
06 Sep 2022 //
GLOBENEWSWIRE
